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InﬂammationMast cells are classically considered innate immune cells that act as ﬁrst responders in many microbial
infections and have long been appreciated as potent contributors to allergic reactions. However, recent
advances in the realm of autoimmunity have made it clear that these cells are also involved in the pathogenic
responses that exacerbate disease. In the murine models of multiple sclerosis, rheumatoid arthritis and
bullous pemphigoid, both the pathogenic role of mast cells and some of their mechanisms of action are shared.
Similar to their role in infection and a subset of allergic responses, mast cells are required for the efﬁcient
recruitment of neutrophils to sites of inﬂammation. Although this mast cell-dependent neutrophil response is
protective in infection settings, it is postulated that neutrophils promote local vascular permeability and
facilitate the entry of inﬂammatory cells that enhance tissue destruction at target sites. However, there is still
much to learn. There is little information regarding mechanisms of mast cell activation in disease. Nor is it
known how many mast cell-derived mediators are relevant and whether interactions with other cells are
implicated in these diseases including T cells, B cells and astrocytes. Here we review the current state of
knowledge about mast cells in autoimmune disease. We also discuss ﬁndings regarding newly discovered
mast cell actions and factors that modulate mast cell function. We speculate that much of this new
information will ultimately contribute to a greater understanding of the full range of mast cell actions in
autoimmunity. This article is part of a Special Issue entitled: Mast cells in inﬂammation.ells in inﬂammation.
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l rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction: The mast cell, the “Jack of all trades” immune cell
Mast cells are members of the innate immune system that develop
from CD34+ hematopoietic precursor cells in the bone marrow and
circulate in the blood in an immature form. Only after they have
established residency in a particular tissue, do they complete their
tissue-speciﬁc differentiation and maturation [1]. Mast cells are
considered ﬁrst line defenders against infections because of their
prevalence in tissues such as the skin, gut, respiratory tract and
urinary tract that form the barriers between self and the environment.
They are also found in close association with blood vessels, lymphatic
vessels and nerves. These anatomical locations license mast cells to
contribute to a multitude of protective and pathologic events
including angiogenesis, wound healing and the exacerbation of
inﬂammation (reviewed in [2–4]).
The potential for mast cells to inﬂuence a wide range of
physiological events also stems from their ability to be activated by
both “immune” and “non-immune” stimuli. Mast cells are infamous
for their role in hypersensitivity reactions where they are activated by
cross-linking of the high afﬁnity IgE receptor (FcεRI). Tissuemast cellsare the major resident cell population expressing FcεRI and IgE-
antigen cross-linking results in the release of several preformed
molecules that are stored in mast cell granules including histamine,
serotonin, tryptase, chymase as well as the lipid-derived mediators
prostaglandin D2 (PGD2) and leukotriene B4 (LTB4) (Fig. 1). These
mediators affect many aspects of the early-phase allergic reactions
such as vasodilation, local or systemic increases in vascular perme-
ability, constriction of smooth muscle and mucus secretion. Such
activation also leads to the release of newly synthesized mediators
(Fig. 1), which can initiate more severe and prolonged late-phase
allergic responses [5].
IgE-independent activation of mast cells is prevalent in non-
allergic responses. Mast cells can be activated by IgG-antigen
complexes, pathogen associated molecular patterns (PAMPs), com-
plement, cell–cell contact, cytokines, certain drugs, hormones and
physical activators such as temperature and pressure. These stimuli
can result in the release of both preformed and newly synthesized
mediators, including cytokines and chemokines, and regulate the
expression of ligands on mast cells that allow direct cell–cell
interaction with T and B cells [5,6] (Fig. 1).
In the last 10 years it has become evident thatmast cells are critical
players in the defense against certain bacterial, parasitic and viral
infections. In bacterial infections such as Citrobacter rodentium, E. coli,
and Heliobactor felis, a major role for mast cells is the production of
Fig. 1. The mast cell, the “jack of all trades” immune cell. The multitude of activators and the many modes of mast cell response account for their ability to impact a variety of
physiological and pathogenic processes. Receptor-binding agonists, physical activators and cell–cell contact can all activate mast cells. Responses to activation are heterogeneous and
include the release of preformed mediators stored within granules and the synthesis and release of new products. Activated mast cells can also respond by increasing the expression
of ligands that mediate cell interactions with T and B cells.
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resulting in the escalation of the host defense [7,8]. In helminth
infections of the gut, mast cells aid in resolving infection by producing
soluble mediators (e.g. leukotrienes, prostaglandins, histamine, Th2-
like cytokines and proteases) that promote luminal ﬂow, nerve
stimulation, gut contractility and moderate intestinal inﬂammation
leading to parasitic expulsion [9,10]. Most studies of mast cells in viral
infections have focused on their role in HIV infection. It has been
proposed in HIV/AIDS that mast cells play two pathogenic roles. First,
mast cells are an inducible reservoir of infectious viral clones [11,12].
Secondly, throughout infection, viral glycoprotein gp120 is shed
throughout infection. Gp120 can then activate when viral glycopro-
tein gp120 is shed throughout viral infection, it activates mast cells
and basophils via IgE bound to FcεRI, resulting in a Th2 dominated
response which down-regulates the protective anti-viral response
[13]. Mast cells have also been implicated in autoimmunity. Here we
review the most recent data that supports a role for mast cells in
various autoimmune diseases. We also discuss new information
regarding mast cell activities in health and disease and speculate on
how this may provide insights into their role in autoimmunity.2. Current models to study mast cells
Although cell co-culture assays have been useful in revealing the
molecular basis of mast cell inﬂuence, the relevance of in vitro
ﬁndings in disease settings is often unclear. The most deﬁnitive
evidence of mast cell contributions in vivo is derived from studies
using two strains of mast cell-deﬁcient mice, (WBxC57BL/6) F1-KitW/
KitWv (W/Wv) and C57BL/6KitWsh/KitWsh (W-sash). These mice carry
mutations in the c-kit gene, historically termed the white spotting
locus (W). These mutations result in reduced tyrosine kinase-
dependent c-kit signaling needed for proper mast cell development
and survival [4,14–17]. Both W/Wv and W-sash mutations also result
in other phenotypic abnormalities. W/Wv mice are anemic, neutro-
penic, have impaired melanogenesis and are sterile [16]. While W-
sashmice are fertile and not anemic, they have neutrophilia, defects in
skin pigmentation, exhibit an anxiety-like phenotype and show a timedependent loss in mast cells with full deﬁciency achieved only at 10–
12 weeks of age [17,18].
To verify mast cell contributions to a speciﬁc phenotype, mast cell
populations can be reconstituted in thesemicewithout prior irradiation
by systemic or local injections of either whole bone marrow or bone
marrow-derivedmast cells (Fig. 2). Such “knock-in” strategies can also
be exploited to determine which local mast cell subpopulation is
relevant in disease, a difﬁcult task given mast cells are ubiquitous in
many tissues. For example, intravenous (i.v.) reconstitution restores
many peripheral tissues but not the parachyma of the CNS [19],
intracranial (i.c.) reconstitution restores mast cells to areas of the
meninges (dura and pia mater) and cervical lymph nodes [20] and
intradermal (i.d.) reconstitution restoresmast cells to the local skin [15]
(Fig. 2). Although these models represent the current standard for the
functional analyses of mast cells, the search for better models continues
and there is a great need for conditional mast cell knock-outs and mast
cell-deﬁcient animals on a variety of genetic backgrounds.
3. Autoimmune disease: Another mast cell-dependent
“hypersensitive” response?
Some features of the immune responses in autoimmune disease
are very much like those of traditional allergic responses. The antigen
target is not inherently harmful and it is the overzealous immune
response that causes the pathology. In addition, similar to allergies, T
cells are important in directing and initiating the immune response to
the target tissue, but other cells are perhaps equally important in
aggravating the inﬂammatory damage. There is a growing body of
evidence that mast cells are involved in the exacerbation of several
autoimmune diseases. Here we summarize the most unequivocal data
from both human and mouse autoimmune disease studies.
3.1. Mast cells and multiple sclerosis (MS)
MS is a progressive demyelinating disease of the central nervous
system (CNS) characterized by the presence of widespread inﬂam-
matory lesions in the brain and spinal cord. Symptoms of MS result
from the interruption of myelinated tracts in the CNS and include
Fig. 2. Systemic and localmast cell reconstitution.Mast cell “knock-in” strategies allow for the analysis ofmast cell-speciﬁc contributions to physiological and pathological events.Mast cell
populations can be derived frommurine bonemarrow culturedwith IL-3 and SCF. There are multiple reconstitution techniques that result in the restoration of mast cells to select sets of
tissues. This technique canbeexploited toassess the requirement ofmast cell residencewithinparticular anatomical locations forparticularphenotypes. Intravenous (i.v.) injectionofmast
cells results in the reconstitution of many but not all of the tissues where mast cells normally reside and include the liver, spleen, lungs, bone marrow, meninges and gut but not the
parenchyma of the CNS. Intradermal (i.d.) injection ofmast cells results in restoration of the local skin and intracranial (i.c.) reconstitution populates some areas of themeninges (dura and
pia mater) and cervical lymph nodes.
59M.E. Walker et al. / Biochimica et Biophysica Acta 1822 (2012) 57–65visual disturbances, bowel and bladder incontinence, as well as
sensory and motor dysfunction. Cognitive deﬁcits are also common
and include memory loss, impaired attention and slowed information
processing [21,22]. Experimental autoimmune encephalomyelitis (EAE)
is a widely studied rodent model of MS that was ﬁrst described over 50
years ago [23,24]. As inMS, EAE is characterized byanearly breachof the
blood–brain barrier (BBB) allowing signiﬁcant inﬂammatory cell
inﬁltration into the CNS and targeted destruction of myelin and
oligodendrocytes, the myelin-producing cells. The resulting demyelin-
ation of axons and often, axonal transection, along with concomitant
edema, leads to progressive paralysis [25,26]. Encephalitogenic CD4+ T
cells speciﬁc for myelin antigens are major contributors to the
pathogenic autoimmune response in EAE. IFNγ-secreting T helper 1
cells (Th1), IL-17-producing Th17 cells and IL-9-producing Th9 cells are
implicated in disease [27]. The speciﬁc role for these cells in MS is still
unclear [28].
Mast cells were ﬁrst observed in the CNS lesions of MS patients
over 100 years ago [29] and data suggesting that mast cells play a role
in MS have continued to accumulate. An increase of mast cells is
commonly observed at sites of inﬂammatory demyelination in the
brain and spinal cord of MS patients as well as in rodents with EAE
[30,31]. Elevated levels of tryptase, a mast cell-speciﬁc protease, are
present in the cerebrospinal ﬂuid of MS patients [32] and microarray
analysis of MS lesions shows that transcripts encoding tryptase,
histamine R1 and FcεRI are signiﬁcantly increased in chronic disease
[33]. In vitro, mast cell proteases degrade myelin protein and myelindirectly stimulates mast cell degranulation [34–36]. Treatment with
inhibitors of mast cell degranulation (proxicromil), a serotonin
receptor antagonist (cyproheptadine) or a depletor of vasoactive
amines in mast cell granules (reserpine) inhibits EAE [37,38].
The most direct evidence for mast cell action in EAE comes from
studies utilizing W/Wv mice in a model of primary progressive (PP)
MS [39]. In this model disease is induced by immunization with
MOG35–55 in CFA along with pertussis toxin. Mast cell deﬁciency leads
to signiﬁcantly less clinical disease that is associated with loss of BBB
permeability and inﬂammatory cell inﬁltration into the parenchyma
of the CNS [20,39]. Recent studies have implicated TNF produced by
meningeal mast cells in these events. Consistent with the well
established ability of mast cells to recruit neutrophils to sites of
infection and allergic inﬂammatory responses, the early disease-
associated entry of neutrophils into the meninges and the CNS
parenchyma is abrogated in the absence of mast cells or mast cell-
derived TNF [20,39].
SJL mice immunized with PLP139–151 in CFA exhibit relapsing
remitting (RR) EAE that mimics themost common form of MS [40,41].
Our laboratory has recently generated mast cell-deﬁcient SJL mice to
study the role of mast cells in RR disease. As in the PP model of MS,
mast cells contribute to severe disease in SJL mice [42]. Conventional
wisdom has dismissed a role for neutrophils in MS because they are
not detected inmatureMS plaques. Yet consistentwith data in PP EAE,
recent studies have demonstrated that neutrophils are required for
BBB permeability and clinical disease in RR EAE [43]. Thus, one common
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activate neutrophils to facilitate BBB permeability and initiate disease. It
is likely that comparisonof RRandPPdisease in thesemast cell-deﬁcient
models will allow the identiﬁcation of other common mechanisms of
mast cell action.3.2. Mast cells and rheumatoid arthritis (RA)
RA is a chronic inﬂammatory disease that can involve many
tissues, although the primary targets of immune destruction are the
synovial joints. In RA the cells of the synovial lining, in particular
synovial ﬁbroblasts (SFs), undergo extensive hyperplasia, forming a
structure termed the “synovial pannus,” which invades and destroys
cartilage and bone. Although RA is considered an autoimmune
disease, no speciﬁc target autoantigen has been identiﬁed. Rheuma-
toid factor, an immunoglobulin with speciﬁcity for the Fc portion of
IgG, and antibodies against citrullinated cyclic peptide are character-
istic in patients with RA [44].
A variety of animal models exist to study RA [44] but three are
most commonly utilized. The K/BxN mouse (KRN T cell receptor
transgenic mouse on the C57BL/6 x NOD background) spontaneously
develops an early onset, rapidly progressive arthritis mediated by
autoantibodies that bind glucose-6-phosphate isomerase. Serum from
K/BxN mice that have developed disease can passively transfer
disease to most recipient strains of mice in autoantibody-induced
arthritis (AIA). Collagen-induced arthritis (CIA) is elicited by
immunization with heterologous type II collagen in CFA. Mast cells
were ﬁrst implicated in the AIA model of RA using two mast cell-
deﬁcient mouse strains, SI/SId and W/Wv. These mice exhibited little
to no clinical or histological evidence of arthritis compared with
control littermates and disease susceptibility after serum transfer was
restored upon reconstitution of mast cells [45].Fig. 3. Common pathogenic mechanisms in autoimmune disease: mast cell-derived TNF and
underlyingmechanisms ofmast cell inﬂuence on disease. In primary progressive EAE, mening
with neutrophil recruitment to the CNS. Similarly in BP, the degranulation and release of
accumulation of neutrophils and skin blistering. Finally, in RA the de novo synthesis of
inﬂammatory cell inﬁltrates including neutrophils in synovial joints. Mast cell-derived trypta
that recruit neutrophils to the joint.Mast cells are normally present in the synovial compartments of
healthy individuals but are found in increased numbers in RA patients.
Furthermore, there is evidence that cytokines and proteases produced
by mast cells, notably TNF, IL-1β, IL-17 and tryptase, are intimately
involved. For example, it has been reported that mast cells are the
main source of IL-17 in human RA synovium [46]. Activated mast cells
present at these sites also produce TNF de novo that in turn induces IL-
1β (Fig. 3) [47]. Mast cell-derived tryptase expressed within the
synovium can form complexes with heparin and act on RASFs to
upregulate neutrophil chemotactic factors in AIA, suggesting an
indirect role for mast cells in neutrophil recruitment (Fig. 3) [48]. In
addition, tryptase-mediated activation of protease-activated receptor
2 (PAR-2) on synovial cells leads to increased vascular permeability
and inﬂammation in the joint and can inhibit Fas-mediated apoptosis
of RASFs contributing to ﬁbroblast hyperplasia and joint damage
[49,50]. In CIA [51] and AIA [52] RASFs were shown to produce IL-33,
which directly activates mast cells to express high levels of
proinﬂammatory cytokines (such as IL-17, IL-1β, IL-6, IL-13, GM-
CSF) and chemokines (MCP-1 and MIP-1α) [46]. These molecules
recruit inﬂammatory cells including neutrophils, as well as promote
an autoreactive Th17 phenotype [46].
3.3. Mast cells and bullous pemphigoid (BP)
Aprominent role formast cells exists in BP, an acquired autoimmune
skindisease characterizedby thepresence of autoantibodies against two
hemidesmosomal antigens, BP230 and BP180, and the presence of
subepidermal blisters [53]. In mice, passive transfer of autoantibodies
directed to the murine BP180 ectodomain triggers a blistering skin
disease that is dependent upon complement activation and neutrophil
inﬁltration and closely mimics the human disease [54,55]. Intradermal
injectionofwild typeneonatalmicewith IgGantibodies directed against
BP180 results in extensive mast cell degranulation in the skin thatthe recruitment of neutrophils. Murine models of MS (EAE), RA and BP have common
eal mast cell-derived TNF is necessary for severe disease and its expression corresponds
preformed mediators including TNF from mast cells resident in the skin result in an
TNF by mast cell results in IL-1β release by macrophages leading to an increase in
se via tryptase–heparin complexes activates synovial ﬁbroblasts to express chemokines
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Conversely, this neutrophil accumulation and the development of skin
lesions are signiﬁcantly diminished in W/Wv mice, but can be restored
to wild type levels if mice are treated with the neutrophil chemoat-
tractant IL-8 at the site of antibody treatment. Neutrophil accumulation
and skin blistering were also blocked when mice were treated with the
mast cell stabilizer cromolyn [53]. Strong evidence also exists for mast
cell involvement in human disease. Degranulated mast cells are
prominent in the skin of BP patients and signiﬁcant levels of histamine,
several mast cell-derived chemoattractants as well as elevated levels of
tryptase are present in the blister ﬂuid of BP patients [56–60].
3.4. Mast cells and type 1 diabetes (T1D)
T1D results froman autoimmune attack against the insulin-producing
β-cells in the islet of langerhans of the pancreas. The resulting failure of
glucose homeostasis damages blood vessels and nerves [61].Widely used
models to study T1D include the non-obese spontaneously diabetic
mouse (NOD), the lymphopenic and spontaneously diabetic BioBreeding
(BB) DRlyp/lyp rat and inducible BB DR (+/+) rat. These rodent models
of diabetes share some features with the human disease. All exhibit a
number of related genetic susceptibility loci and NOD mice have a
profound breakdown in immune regulation, similar to human T1D, that
results in the expansion of autoreactive CD4+ and CD8+ T cells, and
autoantibody-producing B cells, as well as the activation of innate
immune cells that act collectively to destroy insulin-producing β-cells
[61].
The data that supports mast cell involvement in diabetes is still
indirect. Two lines of evidence suggest a role in the spontaneous BB rat
model. First, treatment with the mast cell stabilizer cromolyn
signiﬁcantly delayed disease onset and secondly, mast cell gene
expression proﬁling of the pancreatic lymph nodes revealed an
activated mast cell population in disease [62]. Data from Louvet et al.
showed that while tyrosine kinase inhibitors (c-kit is one of many
tyrosine kinase associated receptors) inhibit and reverse T1D in NOD
mice, speciﬁc c-kit inhibitors were only marginally effective [63].
Preliminarydata fromour laboratoryusingmast cell-deﬁcientNODW/Wv
mice show a signiﬁcant decrease in disease incidence. However a
speciﬁc role for mast cells in disease has yet to be validated because
reconstitution at 4–6 weeks of age fails to restore disease susceptibility.
These observations suggest that either mast cells act earlier in
promoting the insulitis that is a prerequisite for full disease or that
another c-kit related mechanism is operational [Quirion et al.,
manuscript in preparation]. Notably, mast cells have also been
implicated in the pathogenesis of non-autoimmune diet-induced
obesity and diabetes in mice, although how mast cells function in
these conditions has not been delineated [64].
3.5. Mast cells in other autoimmune diseases
The most convincing evidence of mast cell inﬂuence in autoim-
munity occurs within the context of the diseases discussed above.
However, mast cells are implicated in other autoimmune diseases
including Guillain–Barré Syndrome, Graves’ opthamology, pemphigus
vulgaris, systemic lupus erythematosus and Sjogren's syndrome [6].
Data linking mast cells to these conditions comes primarily from
observations of mast cell activation during disease or from use of mast
cell targeted therapies that result in decreased disease severity [65].
4. Potential roles of mast cells in autoimmune disease
The speciﬁc mechanisms of mast cell action in autoimmunity are
not completely understood. As a “jack of all trades,”mast cells interact
with and modulate the function of many cells types, thus giving them
the potential to affect these disease processes in a variety of ways. For
example,mast cells have the potential to inﬂuence T cell priming throughthe expressionofMHCclass II, providedirect costimulationvia expression
of cell surface receptors and enhance T cell proliferation and activation
through the wide variety of cytokines they express. Mast cells also affect
dendritic cell maturation, migration, and function, and can indirectly
affect T cell function through DC function. (for amore complete review of
mast cell interactions with other immune cells see [2,6]). Here we
summarize only the most recent reports on the interaction of mast cells
with Tregs, Th17 cells, B cells, cells of theCNS, and the relationship ofmast
cells with other recently recognized molecules of interest. While these
studies are not in the context of autoimmune disease, the results may be
applicable to our ultimate understanding of this group of diseases.
5. Direct cell interactions with mast cells
It has been appreciated for some time that mast cells can cooperate
with other cell types such as dendritic cells and T effector cells to
enhance activation and migration either directly through cell–cell
interactions or via secreted products [2,6]. As discussed below, recent
data has emerged that delineates new mast cell interactions with
many other cell types that have established and critical roles in
autoimmune diseases.
5.1. Mast cells and T regulatory cell (Treg) interactions
Tregs, deﬁned by their expression of CD4, CD25 and FoxP3 and the
ability to suppress T effector cell responses, are among the main cell
types that maintain immune homeostasis [66]. Tregs have a major
role in mediating autoreactive T cell tolerance and there is much
evidence that aberrant regulatory T cell activity contributes to
autoimmunity. As mast cells and Treg cells are often found in close
proximity in secondary lymphoid organs and speciﬁc sites of tissue
inﬂammation, it is not surprising that their interaction results in
effects on the functional capabilities of both cell types.
The OX40–OX40L axis is perhaps the best-deﬁned molecular
determinant of mast cell-Treg interactions. Mast cells constitutively
express OX40L, while OX40 is constitutively expressed on Treg cells.
Both in vitro and in vivo studies demonstrate that Tregs are able to
down regulate FcεRI expression and inhibit FcεRI dependent mast cell
degranulation [67,68]. Conversely, mast cells can reverse Treg
suppression of T effector cells and reduce T effector cell susceptibility
to Treg suppression [69] (Fig. 4).
Mast cells also suppress Treg activity in an OX40L-independent
manner. In a model of skin allograft tolerance mast cells promote
allograft rejection. Graft recipients are tolerized to alloantigens by a
combination of anti-CD154 and i.v. transfusion of allogenic cells prior
to skin grafting. In this setting, mast cell degranulation triggered by
IgE and antigen leads to a transient loss of Treg function resulting in
the breakdown of peripheral tolerance [70]. There is evidence that
histamine is responsible for this effect. Blocking of the histamine 1
receptor in Treg cells using the H1 receptor speciﬁc antagonist,
loratadine, rescues Treg cell suppressor function in the presence of
exogenous histamine [71]. Clearly the dynamic and reciprocal
relationship between these two cells needs to be further explored in
the context of autoimmunity.
5.2. Mast cells and Treg–Th17 cell plasticity
Th17 cells are CD4+ T cells that are deﬁned by their expression of
the transcription factor RORγt and a variety of hallmark cytokines
including IL-17a and IL-17f. Together with IFNγ-producing Th1 cells,
they are implicated in themousemodels of MS, RA and T1D [72]. Th17
cells arise from a naïve CD4+ T cell upon antigen activation under the
inﬂuence of a unique cytokine microenvironment including some
combination of TGFβ, IL-6, IL-21, IL-23 and IL-1β in mice and humans.
TGFβ alone is essential for the development of Tregs and this
differentiation can be inhibited by IL-6 (Fig. 4). Multiple lines of
Fig. 4. Direct cell interactions involvingmast cells with potential to affect autoimmunedisease.Mast cells produce cytokines that can promote distinct CD4+T cell fates.Mast cell-derived
IL-6 and TNF can actwith Treg-derived TGFβ, to skew T effector cells (CD4+CD25-) to a proinﬂammatory Th17 phenotype. The direct interaction of OX40L-OX40 onmast cells and Tregs
respectively leads to the inhibition of FcεRI expression and degranulation on mast cells and to an inability of Tregs to suppress effector T cell activity. Mast cells affect B cell survival,
proliferation and differentiation into IgA secreting plasma cells through the production of IL-6 and CD40–CD40L interactions. The production of IgE antibodies impacts both mast cell
survival and activation potential. IgG triggering of FcγRII and FcγRIII expressed onmast cells are important in autoimmune diseases such as EAE, BP, RA and systemic lupus. Astrocytes, a
type ofmicroglia, are of particular interest in immunemediated diseases of the CNS.Mast cells and astrocytes have a dynamic relationship as a result of their coincident activation through
CD40–CD40L. The resulting mast cell activation results in the release of IL-33 and IL-1β release from glial cells, which further promotes mast cell activation.
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protective Tregs have a reciprocal developmental relationship. The
balance of cytokines in the local environment, which regulate the
expression and function of the respective transcription factors RORγt
and FoxP3, determine the relative frequency of Th17 and Treg cells
[73]. Under certain conditions mast cells express all of the relevant
cytokines (IL-6, IL-21, IL-23, and TGFβ) that drive Th17 and Treg cell
differentiation and plasticity. In mast cell-T cell co-culture experi-
ments activated BMMC produce IL-6 and TNF, which together with
TGFβ-producing Treg cells, can induce IL-17 production in effector T
cells (CD4+CD25-). These mast cell-derived cytokines can also
directly promote Treg skewing to a Th17 phenotype [69]. This
interaction may play an important role in vivo as Tregs, T effector
cells and mast cells co-localize at sites of T cell priming as well as
within tissues where secondary activation events occur. Such effects
of mast cells on T cell differentiation are also observed in certain
tumor microenvironments where mast cell-derived IL-6 contributes
to a proinﬂammatory Th17-dominant environment leading to
concomitant autoimmunity [74] (Fig. 4).
5.3. Mast cells and B cells
Mast cells express a number of B cell-modulating molecules as
well as Ig receptors suggesting an intimate connection between thesetwo cell types. Monomeric IgE bound to FcεRI without antigen
promotes the survival and priming of mast cells [75]. In addition to
FcεRI, human and murine mast cells express the IgG receptors FcγRII
and FcγRIII. When cross-linked with IgG-antigen complexes these
receptors are potent inducers of degranulation [76]. FcγRII and FcγRIII
are important in autoimmune diseases classiﬁed as type II and III
hypersensitivity diseases such as BP, RA and SLE and in the type IV
hypersensitivity disease EAE [6]. It was demonstrated that low mast
cell concentrations are effective in inﬂuencing B cell survival and
proliferation in vitro, regardless of the state of mast cell activation.
Mast cells also promote the differentiation of B cells into CD138+
plasma cells and selective IgA secretion. All of these effects are
dependent on mast cell-derived IL-6 and the expression of CD40–
CD40L on B cells and mast cells respectively [77] (Fig.4).
5.4. Mast cells and CNS cells
There are also a number of mast cell interactionswith resident CNS
cells. The best-described interaction is with the astrocyte, a cell that
plays a critical role in MS and EAE [78]. Astrocytes, a subtype of glial
cells, are the most abundant cell type in the brain. They affect
neuronal function via the release of neurotropic factors, contribute to
the metabolism of neurotransmitters, regulate BBB permeability and
can present antigen to T cells. Mast cells and astrocytes have a
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thalamus and at perivascular sites. Mast cell-astrocyte co-culture
results in the activation of both cell types, an event dependent on
CD40–CD40L and the release of mediators including histamine,
leukotrienes, cytokines and chemokines [79] (Fig. 4). The combination
of PAMPs and ATP activates glia to produce IL-33 and IL-1β directly
eliciting the production of large amounts of inﬂammatory cytokines
by mast cells [80]. IL-13 is also expressed by mast cells in this
inﬂammatory cascade and activates glia to produce other proinﬂam-
matory molecules such as arginase 1, IL-6, MCP-1 and TNF [79,81].
6. Mast cell products and activators
The appreciation of molecules that are intimately involved in mast
cell function is growing and it is of interest that some of these newly
identiﬁed molecules have established roles in autoimmune disease.
Although their expression bymast cells in autoimmunity has not been
veriﬁed, they are good candidates for further exploration.
6.1. Osteopontin
Osteopontin is a protein that is clearly implicated in MS and EAE. It
is member of the Sibling (small integrin binding, N-linked glycopro-
teins) family of proteins. Its early characterization in these diseases
was based on its inducible expression on inﬂamed endothelium in the
extracellular matrix of perivascular cuffs [82]. Together with VCAM-1
it is a binding partner of α4b1 integrin, a homing molecule expressed
on lymphocytes that are trafﬁcking to the CNS. However, osteopontin
has several additional binding partners and also participates in bone
remodeling, wound healing, dystrophic calciﬁcation, coronary rest-
enosis and tumor cell metastasis [83,84]. Osteopontin is produced by a
variety of immune cells including macrophages, activated T cells,
myeloid DCs, plasmacytoid DCs, NKT and mast cells [85–89]. In both
MS and EAE, osteopontin is associated with relapses through at least
two proposed mechanisms including the induction of proinﬂamma-
tory T cell activity and the inhibition of autoreactive T cell apoptosis
[82].
Mast cell production of osteopontinwas ﬁrst reported by Nagasaka
et al. in fetal skin-derived mast cells after ionomycin stimulation or
FcεRI cross-linking [89]. They also demonstrated that mice with
targeted deletions in the osteopontin gene displayed reduced IgE-
mediated passive cutaneous anaphylaxis, perhaps due to its ability to
regulate mast cell migration to sites of inﬂammation. Osteopontin
transcripts together with a number of mast cell-speciﬁc mRNAs are
among those whose expression is signiﬁcantly increased in CNS
lesions compared to normal brain tissue [33]. Although there is no
direct link between mast cell expression of osteopontin and MS, the
presence of mast cells at sites where this protein is highly expressed in
inﬂammatory CNS plaques and its ability to modulate mast cell
function is intriguing.
6.2. Substance P (SP)
The CNS is generally considered impermeable to immune cell
inﬁltration, yet evidence is accumulating that suggests this is not an
accurate depiction. It is now appreciated that there is a dynamic
relationship between the CNS and the cells of the peripheral immune
system. One mode of crosstalk is mediated through neuropeptides
and their receptors [90]. Of relevance to autoimmunity is the
neuropeptide SP, a monomer peptide secreted by nerves, macro-
phages, eosinophils, lymphocytes and DCs. Unlike most neuropep-
tides which are anti-inﬂammatory, SP is proinﬂammatory and may
play a role in the induction of immune responses in the CNS [91]. SP
acts by binding to the neurokinin-1 receptor, which is widely
expressed, and this interaction contributes to other inﬂammatory
diseases such as atopic dermatitis, asthma, sarcoidosis, chronicbronchitis, irritable bowel syndrome and RA [90,92]. SP is also a
potent activator of mast cell gene expression including TNF
expression [93]. Considering the contribution of mast cell-derived
TNF in multiple autoimmune diseases (Fig. 3), it is possible that SP is
one of the critical activators of mast cells in autoimmunity.
6.3. IL-33
IL-33 is a member of the IL-1 family of cytokines that includes IL-
1α, IL-1β and IL-18. In contrast to other IL-1 related cytokines, except
for IL-1α, IL-33 is primarily localized in the nucleus and it associates
with chromatin where it can bind to the surface of nucleosomes and
affect chromatin remodeling [94,95]. It is crucial for the induction of
Th2 type cytokine-associated immune responses and thus has been
extensively studied in the context of allergic disease where it has
proinﬂammatory effects and in helminth infections where it is
protective [96]. In models of anaphylaxis IL-33 directly induces mast
cell degranulation after IgE sensitization. There appears to be an
autocrine inﬂammatory loop induced by IL-33 in mast cells. IL-33 is
produced by murine mast cells and mast cells also constitutively
express ST2, a receptor subunit that together with IL-1 receptor
accessory protein (IL-1RAcP) makes up the heterodimeric IL-33
receptor. Notably, similar to IL-3 and SCF, IL-33 can also directly
induce cytokine and chemokine secretion from mast cells without
affecting degranulation [94,95]. The proinﬂammatory activities of IL-
33 and its link to mast cells make it a good candidate for studies in
mast cell-dependent inﬂammatory autoimmune diseases [96].
7. Conclusions
A wealth of new data has increased our appreciation for a
signiﬁcant, disease-exacerbating role for mast cells in autoimmunity.
Although there are still many questions to be answered regarding
how mast cells are activated, the extent of mast cell involvement in
various diseases and their speciﬁc mode of action, many of these
studies reveal common themes. First, it is clear that mast cells
exacerbate, not limit, disease. Mast cells could conceivably exert anti-
inﬂammatory effects on disease via a variety of mediators and
potentially alter Treg cell function, but are ﬁrst and foremost acting as
proinﬂammatory cells. Secondly, in at least three models of
autoimmune disease (EAE, BP and RA) mast cells promote inﬂam-
mation and disease severity through a commonmechanism involving
TNF and/or neutrophil recruitment (Fig. 3). Although neutrophils are
short-lived cells that have been largely dismissed as major players in
many autoimmune diseases, their involvement in multiple disease
models is hard to ignore. It is also notable thatmast cells are responsible
for eliciting neutrophil inﬁltration that promotes inﬂammation regard-
less of whether that outcome is protective (in infections) or pathologic
(in contact hypersensitivity and autoimmunity). There is now strong
rationale for the serious analysis ofmast cell targeted therapies thatmay
alter disease severity and progression in human patients.
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